Nirmatrelvir (BioDeep_00000843529)
代谢物信息卡片
Nirmatrelvir
化学式: C23H32F3N5O4 (499.24062680000003)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)C(F)(F)F)C(=O)NC(CC3CCNC3=O)C#N)C
InChI: InChI=1S/C23H32F3N5O4/c1-21(2,3)16(30-20(35)23(24,25)26)19(34)31-10-13-14(22(13,4)5)15(31)18(33)29-12(9-27)8-11-6-7-28-17(11)32/h11-16H,6-8,10H2,1-5H3,(H,28,32)(H,29,33)(H,30,35)/t11-,12-,13-,14-,15-,16+/m0/s1
描述信息
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C190795 - SARS-CoV-2 Protease Inhibitor
C254 - Anti-Infective Agent > C281 - Antiviral Agent > C190794 - SARS-CoV-2 Antiviral Agent
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mengwei Zhu, Tiantian Fu, Mengyuan You, Junyuan Cao, Hanxi Yang, Xinyao Chen, Qiumeng Zhang, Yechun Xu, Xiangrui Jiang, Leike Zhang, Haixia Su, Yan Zhang, Jingshan Shen. Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety.
Bioorganic & medicinal chemistry.
2023 05; 87(?):117316. doi:
10.1016/j.bmc.2023.117316. [PMID: 37187077] - Zhujun Cao, Weiyi Gao, Hong Bao, Haiyan Feng, Shuya Mei, Peizhan Chen, Yueqiu Gao, Zhilei Cui, Qin Zhang, Xianmin Meng, Honglian Gui, Weijing Wang, Yimei Jiang, Zijia Song, Yiqing Shi, Jing Sun, Yifei Zhang, Qing Xie, Yiping Xu, Guang Ning, Yuan Gao, Ren Zhao. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
The New England journal of medicine.
2023 02; 388(5):406-417. doi:
10.1056/nejmoa2208822. [PMID: 36577095] - Wenying Yu, Yucheng Zhao, Hui Ye, Nanping Wu, Yixian Liao, Nannan Chen, Zhiling Li, Ning Wan, Haiping Hao, Honggao Yan, Yibei Xiao, Maode Lai. Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
Journal of medicinal chemistry.
2022 12; 65(24):16252-16267. doi:
10.1021/acs.jmedchem.2c00954. [PMID: 36503248] - Yao Zhao, Chao Fang, Qi Zhang, Ruxue Zhang, Xiangbo Zhao, Yinkai Duan, Haofeng Wang, Yan Zhu, Lu Feng, Jinyi Zhao, Maolin Shao, Xiuna Yang, Leike Zhang, Chao Peng, Kailin Yang, Dawei Ma, Zihe Rao, Haitao Yang. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332.
Protein & cell.
2022 09; 13(9):689-693. doi:
10.1007/s13238-021-00883-2. [PMID: 34687004] - Raymond K Hau, Stephen H Wright, Nathan J Cherrington. PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients.
Clinical and translational science.
2022 07; 15(7):1599-1605. doi:
10.1111/cts.13292. [PMID: 35505633] - Ryuta Uraki, Maki Kiso, Shun Iida, Masaki Imai, Emi Takashita, Makoto Kuroda, Peter J Halfmann, Samantha Loeber, Tadashi Maemura, Seiya Yamayoshi, Seiichiro Fujisaki, Zhongde Wang, Mutsumi Ito, Michiko Ujie, Kiyoko Iwatsuki-Horimoto, Yuri Furusawa, Ryan Wright, Zhenlu Chong, Seiya Ozono, Atsuhiro Yasuhara, Hiroshi Ueki, Yuko Sakai-Tagawa, Rong Li, Yanan Liu, Deanna Larson, Michiko Koga, Takeya Tsutsumi, Eisuke Adachi, Makoto Saito, Shinya Yamamoto, Masao Hagihara, Keiko Mitamura, Tetsuro Sato, Masayuki Hojo, Shin-Ichiro Hattori, Kenji Maeda, Riccardo Valdez, Moe Okuda, Jurika Murakami, Calvin Duong, Sucheta Godbole, Daniel C Douek, Ken Maeda, Shinji Watanabe, Aubree Gordon, Norio Ohmagari, Hiroshi Yotsuyanagi, Michael S Diamond, Hideki Hasegawa, Hiroaki Mitsuya, Tadaki Suzuki, Yoshihiro Kawaoka. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Nature.
2022 07; 607(7917):119-127. doi:
10.1038/s41586-022-04856-1. [PMID: 35576972] - Ravi Shankar P Singh, Sima S Toussi, Frances Hackman, Phylinda L Chan, Rohit Rao, Richard Allen, Lien Van Eyck, Sylvester Pawlak, Eugene P Kadar, Frances Clark, Haihong Shi, Annaliesa S Anderson, Michael Binks, Sandeep Menon, Gianluca Nucci, Arthur Bergman. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.
Clinical pharmacology and therapeutics.
2022 Jul; 112(1):101-111. doi:
10.1002/cpt.2603. [PMID: 35388471] - Rita Rubin. From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.
JAMA.
2022 06; 327(24):2380-2382. doi:
10.1001/jama.2022.9925. [PMID: 35675094] - J Reina, C Iglesias. [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination].
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.
2022 Jun; 35(3):236-240. doi:
10.37201/req/002.2022. [PMID: 35183067] - Samantha E Greasley, Stephen Noell, Olga Plotnikova, RoseAnn Ferre, Wei Liu, Ben Bolanos, Kimberly Fennell, Jennifer Nicki, Tim Craig, Yuao Zhu, Al E Stewart, Claire M Steppan. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
The Journal of biological chemistry.
2022 06; 298(6):101972. doi:
10.1016/j.jbc.2022.101972. [PMID: 35461811] - Lennart Brewitz, Jos J A G Kamps, Petra Lukacik, Claire Strain-Damerell, Yilin Zhao, Anthony Tumber, Tika R Malla, Allen M Orville, Martin A Walsh, Christopher J Schofield. Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease.
ChemMedChem.
2022 05; 17(9):e202200016. doi:
10.1002/cmdc.202200016. [PMID: 35085423] - Heather Eng, Alyssa L Dantonio, Eugene P Kadar, R Scott Obach, Li Di, Jian Lin, Nandini C Patel, Britton Boras, Gregory S Walker, Jonathan J Novak, Emi Kimoto, Ravi Shankar P Singh, Amit S Kalgutkar. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.
Drug metabolism and disposition: the biological fate of chemicals.
2022 05; 50(5):576-590. doi:
10.1124/dmd.121.000801. [PMID: 35153195] - Emmanuel Heilmann, Francesco Costacurta, Stephan Geley, Seyad Arad Mogadashi, Andre Volland, Bernhard Rupp, Reuben Stewart Harris, Dorothee von Laer. A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition.
Communications biology.
2022 04; 5(1):391. doi:
10.1038/s42003-022-03277-0. [PMID: 35478219] - Daniel W Kneller, Hui Li, Gwyndalyn Phillips, Kevin L Weiss, Qiu Zhang, Mark A Arnould, Colleen B Jonsson, Surekha Surendranathan, Jyothi Parvathareddy, Matthew P Blakeley, Leighton Coates, John M Louis, Peter V Bonnesen, Andrey Kovalevsky. Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.
Nature communications.
2022 04; 13(1):2268. doi:
10.1038/s41467-022-29915-z. [PMID: 35477935] - Jian Li, Cheng Lin, Xuelan Zhou, Fanglin Zhong, Pei Zeng, Yang Yang, Yuting Zhang, Bo Yu, Xiaona Fan, Peter J McCormick, Rui Fu, Yang Fu, Haihai Jiang, Jin Zhang. Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332.
Journal of virology.
2022 04; 96(8):e0201321. doi:
10.1128/jvi.02013-21. [PMID: 35389231] - Gerd Mikus, Kathrin I Foerster, Theresa Terstegen, Cathrin Vogt, André Said, Martin Schulz, Walter E Haefeli. Oral Drugs Against COVID-19.
Deutsches Arzteblatt international.
2022 Apr; 119(15):263-269. doi:
10.3238/arztebl.m2022.0152. [PMID: 35302484] - Sven Ullrich, Kasuni B Ekanayake, Gottfried Otting, Christoph Nitsche. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
Bioorganic & medicinal chemistry letters.
2022 04; 62(?):128629. doi:
10.1016/j.bmcl.2022.128629. [PMID: 35182772] - Jennifer Hammond, Heidi Leister-Tebbe, Annie Gardner, Paula Abreu, Weihang Bao, Wayne Wisemandle, MaryLynn Baniecki, Victoria M Hendrick, Bharat Damle, Abraham Simón-Campos, Rienk Pypstra, James M Rusnak. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
The New England journal of medicine.
2022 04; 386(15):1397-1408. doi:
10.1056/nejmoa2118542. [PMID: 35172054] - Suwicha Patnin, Arthit Makarasen, Pongsit Vijitphan, Apisara Baicharoen, Apinya Chaivisuthangkura, Mayuso Kuno, Supanna Techasakul. Computational Screening of Phenylamino-Phenoxy-Quinoline Derivatives against the Main Protease of SARS-CoV-2 Using Molecular Docking and the ONIOM Method.
Molecules (Basel, Switzerland).
2022 Mar; 27(6):. doi:
10.3390/molecules27061793. [PMID: 35335157] - N R Catlin, C J Bowman, S N Campion, J R Cheung, W S Nowland, J G Sathish, C M Stethem, L Updyke, G D Cappon. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models.
Reproductive toxicology (Elmsford, N.Y.).
2022 03; 108(?):56-61. doi:
10.1016/j.reprotox.2022.01.006. [PMID: 35101563] - Andreas Luttens, Hjalmar Gullberg, Eldar Abdurakhmanov, Duy Duc Vo, Dario Akaberi, Vladimir O Talibov, Natalia Nekhotiaeva, Laura Vangeel, Steven De Jonghe, Dirk Jochmans, Janina Krambrich, Ali Tas, Bo Lundgren, Ylva Gravenfors, Alexander J Craig, Yoseph Atilaw, Anja Sandström, Lindon W K Moodie, Åke Lundkvist, Martijn J van Hemert, Johan Neyts, Johan Lennerstrand, Jan Kihlberg, Kristian Sandberg, U Helena Danielson, Jens Carlsson. Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses.
Journal of the American Chemical Society.
2022 02; 144(7):2905-2920. doi:
10.1021/jacs.1c08402. [PMID: 35142215] - Eric J Rubin, Lindsey R Baden, Stephen Morrissey. Audio Interview: A New Antiviral against Covid-19.
The New England journal of medicine.
2022 02; 386(7):e25. doi:
10.1056/nejme2202349. [PMID: 35172062] - Rana Abdelnabi, Caroline S Foo, Dirk Jochmans, Laura Vangeel, Steven De Jonghe, Patrick Augustijns, Raf Mols, Birgit Weynand, Thanaporn Wattanakul, Richard M Hoglund, Joel Tarning, Charles E Mowbray, Peter Sjö, Fanny Escudié, Ivan Scandale, Eric Chatelain, Johan Neyts. The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern.
Nature communications.
2022 02; 13(1):719. doi:
10.1038/s41467-022-28354-0. [PMID: 35169114] - Emily G McDonald, Todd C Lee. Nirmatrelvir-ritonavir for COVID-19.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
2022 02; 194(6):E218. doi:
10.1503/cmaj.220081. [PMID: 35115376] - Simar Singh Bajaj, Fatima Cody Stanford. COVID-19: LMICs need antivirals as well as vaccines.
Nature.
2022 02; 602(7895):33. doi:
10.1038/d41586-022-00220-5. [PMID: 35105995] - Laura Vangeel, Winston Chiu, Steven De Jonghe, Piet Maes, Bram Slechten, Joren Raymenants, Emmanuel André, Pieter Leyssen, Johan Neyts, Dirk Jochmans. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
Antiviral research.
2022 02; 198(?):105252. doi:
10.1016/j.antiviral.2022.105252. [PMID: 35085683] - Joseph Heskin, Scott J C Pallett, Nabeela Mughal, Gary W Davies, Luke S P Moore, Michael Rayment, Rachael Jones. Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management.
Lancet (London, England).
2022 01; 399(10319):21-22. doi:
10.1016/s0140-6736(21)02657-x. [PMID: 34973713] - Marina Macchiagodena, Marco Pagliai, Piero Procacci. Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease.
Journal of molecular graphics & modelling.
2022 01; 110(?):108042. doi:
10.1016/j.jmgm.2021.108042. [PMID: 34653812] - George J Kontoghiorghes, Stella Fetta, Christina N Kontoghiorghe. The need for a multi-level drug targeting strategy to curb the COVID-19 pandemic.
Frontiers in bioscience (Landmark edition).
2021 12; 26(12):1723-1736. doi:
10.52586/5064. [PMID: 34994185] - Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson, Lisa Aschenbrenner, Melissa Avery, Simon Berritt, Britton Boras, Rhonda D Cardin, Anthony Carlo, Karen J Coffman, Alyssa Dantonio, Li Di, Heather Eng, RoseAnn Ferre, Ketan S Gajiwala, Scott A Gibson, Samantha E Greasley, Brett L Hurst, Eugene P Kadar, Amit S Kalgutkar, Jack C Lee, Jisun Lee, Wei Liu, Stephen W Mason, Stephen Noell, Jonathan J Novak, R Scott Obach, Kevin Ogilvie, Nandini C Patel, Martin Pettersson, Devendra K Rai, Matthew R Reese, Matthew F Sammons, Jean G Sathish, Ravi Shankar P Singh, Claire M Steppan, Al E Stewart, Jamison B Tuttle, Lawrence Updyke, Patrick R Verhoest, Liuqing Wei, Qingyi Yang, Yuao Zhu. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.
Science (New York, N.Y.).
2021 Dec; 374(6575):1586-1593. doi:
10.1126/science.abl4784. [PMID: 34726479] - Matteo Pavan, Giovanni Bolcato, Davide Bassani, Mattia Sturlese, Stefano Moro. Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332.
Journal of enzyme inhibition and medicinal chemistry.
2021 Dec; 36(1):1646-1650. doi:
10.1080/14756366.2021.1954919. [PMID: 34289752] - Sylwester Drożdżal, Jakub Rosik, Kacper Lechowicz, Filip Machaj, Bartosz Szostak, Jarosław Przybyciński, Shahrokh Lorzadeh, Katarzyna Kotfis, Saeid Ghavami, Marek J Łos. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
2021 12; 59(?):100794. doi:
10.1016/j.drup.2021.100794. [PMID: 34991982] - Marina Macchiagodena, Maurice Karrenbrock, Marco Pagliai, Piero Procacci. Virtual Double-System Single-Box for Absolute Dissociation Free Energy Calculations in GROMACS.
Journal of chemical information and modeling.
2021 11; 61(11):5320-5326. doi:
10.1021/acs.jcim.1c00909. [PMID: 34723516] - Sven Ullrich, Vishnu M Sasi, Mithun C Mahawaththa, Kasuni B Ekanayake, Richard Morewood, Josemon George, Laura Shuttleworth, Xiaobai Zhang, Cassidy Whitefield, Gottfried Otting, Colin Jackson, Christoph Nitsche. Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors.
Bioorganic & medicinal chemistry letters.
2021 10; 50(?):128333. doi:
10.1016/j.bmcl.2021.128333. [PMID: 34418570] - Carlos A Ramos-Guzmán, J Javier Ruiz-Pernía, Iñaki Tuñón. Computational simulations on the binding and reactivity of a nitrile inhibitor of the SARS-CoV-2 main protease.
Chemical communications (Cambridge, England).
2021 Sep; 57(72):9096-9099. doi:
10.1039/d1cc03953a. [PMID: 34498651] - Bilal Ahmad, Maria Batool, Qurat Ul Ain, Moon Suk Kim, Sangdun Choi. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations.
International journal of molecular sciences.
2021 Aug; 22(17):. doi:
10.3390/ijms22179124. [PMID: 34502033]